Brief: EQRx And Geisinger Sign MoU To Provide Access To Innovative Cancer Medicines At Radically Lower Costs
07/01/2022 14:49
Jan 7 (Reuters) - EQRx Inc EQRX.O :
* EQRX AND GEISINGER SIGN MEMORANDUM OF UNDERSTANDING TO
PROVIDE
ACCESS TO INNOVATIVE CANCER MEDICINES AT RADICALLY LOWER COSTS
* EQRX INC - PARTIES ANTICIPATE THAT COMMERCIAL AGREEMENT
WOULD
INITIALLY FOCUS ON CO'S TWO LEAD ONCOLOGY PROGRAMS, AUMOLERTINIB
AND SUGEMALIMAB
* EQRX INC - PARTIES ANTICIPATE THAT COMMERCIAL AGREEMENT
COULD BE
EXPANDED TO CO'S OTHER PIPELINE PROGRAMS
Source text for Eikon: ID:nGNX1ttBRT
Further company coverage: EQRX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on EQRx
See all newsBrief: Leading Independent Proxy Advisory Firms ISS And Glass Lewis Recommend Revolution Medicines Stockholders Vote "FOR" Proposed Acquisition Of EQRx, Inc
Brief: Revolution Medicines Inc Says Will Acquire EQRx In An All-Stock Transaction
U.S. RESEARCH ROUNDUP- Cigna Group, McKesson, Zscaler
Brief: EQRx posts Q1 EPS USD -0.17
Brief: EQRx Says Jami Rubin Will Step Down As Chief Financial Officer